Navigation Links
Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery

t.

To date, rivaroxaban is the most studied oral direct Factor Xa inhibitor in development. More than 15,000 patients have been evaluated in the completed phase II programs and enrolled thus far in the phase III programs. More than 40,000 patients are expected to be evaluated in total.

The RECORD3 trial is part of the joint clinical development program led by J&JPRD and Bayer HealthCare. Upon regulatory approval, rivaroxaban will be commercialized in the United States by Scios Inc. and Ortho-McNeil, Inc. Bayer Schering Pharma will market rivaroxaban throughout the rest of the world.

The companies plan to submit regulatory filings for the prevention of VTE in orthopaedic surgery in late 2007 in Europe and in 2008 in the United States.

About Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD)

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., is part of Johnson & Johnson, the world's most broadly based producer of healthcare products. J&JPRD is headquartered in Raritan, NJ, and has facilities throughout Europe and the United States. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas to address unmet medical needs worldwide.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment

Post Your Comments:
(Date:11/25/2009)...a, Nov. 25 /PRNewswire-Asia-FirstCall/ -- China Sk...he Company") (Nasdaq: CSKI ), a,leading fully int...ucing,over-the-counter drugs in the People,s Repub...pany recently passed the Chinese National Institut... Products ("ICPBP") examination,for two of its new...
(Date:11/25/2009)... Nov. 25 According to Millennium R...al technology market intelligence, the nearly $3 b...continue to see rapid growth over the next five ye...S Markets for Trauma Devices 2010 report finds ...he next five years, with competitors introducing s...
(Date:11/25/2009)...herlands and JOHANNESBURG, November 25 /PRNewswire... Pyxis Discovery announced today,that they have si...oth,companies, services. , Pyxis,s world ...xpertise,will be coupled with iThemba,s service di...y support to projects identified through Pyxis,in...
Breaking Medicine Technology:China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2Home For the Holidays 3A MyShrink com Announces the Second in its Successful Six Part Webinar Series 3A 26quot 3BAbandonment 3A The Hidden Fear 26quo 62006 1Home For the Holidays 3A MyShrink com Announces the Second in its Successful Six Part Webinar Series 3A 26quot 3BAbandonment 3A The Hidden Fear 26quo 62006 2Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 62004 1Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 62004 2Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 62004 3Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 62004 4NCL Security Launches EyeCentral Video Platform for the Security Industry to Generate Recurring Monthly Revenue for Central Stations and Security Deal 62002 1NCL Security Launches EyeCentral Video Platform for the Security Industry to Generate Recurring Monthly Revenue for Central Stations and Security Deal 62002 2
..., April 17 Schering-Plough,Corporation (NYSE: SG...nt of,chronic hepatitis C virus (HCV) infection, a...dy as well as from several other clinical studies,...ETOL(R) (ribavirin, USP),combination therapy will ...tudy of the Liver (EASL) 43rd annual meeting in Mi...
... April 16 Kosan Biosciences,Incorporated (Nasdaq:...tary,nuclear export inhibitors (NEI) showing poten...ility in leukemia xenograft models, and further,el...orrelating inhibition,of the target CRM1 with indu...pared to normal cells. Data on Kosan,s NEIs were p...
Other Medicine Technology:Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 7Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 8Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 9Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 2Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 3Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 4
(Date:11/27/2009)... Biotech firm Replikins Ltd. tod...1N1 virus genomic data. It shows that the lethali...s.d. 4.5) during the virus,s current outbreak in t...his week of 2.0 (s.d. 0.1). The H1N1 infectivity c... Boston (PRWEB) November 27, 2009 -- Bio...
(Date:11/27/2009)... , NEUILLY-SUR-SEINE, France, Nov. 27 /PRNewsw... professional cycling team dedicated to ethical sp...ng champions, announced today that it will become ...itions Optical as a new sponsor of the team. Trans... of adaptive eyewear, offering the most advanced p...
(Date:11/27/2009)... rates to bring unprecedented medical, economic bu...7 (HealthDay News) -- The number of people with di...over the next 25 years, a new study predicts. ,...million people with the disease, up from 23.7 mill...ating people with diabetes will triple, the study ...
(Date:11/27/2009)... Specialist manufacturers who us...s are saving millions of dollars by bringing in te...ss. Increasing numbers of pro-active medical manuf...at the concept stage of their projects, ensuring t...esign processes or potentially outdated technology...
(Date:11/26/2009)...e next 25 years, the number of Americans living wi....7 million in 2009 to 44.1 million in 2034. Over t...riple, rising from $113 billion to $336 billion, e... researchers based at the University of Chicago re... The number of those with diabetes covered by Medi...
Breaking Medicine News(10 mins):Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3
..., SAN DIEGO, Jan. 6 NuVasive, Inc. (Nasdaq: NU...ng products for minimally disruptive surgical trea...kianov, Chairman and Chief Executive Officer, is s...2009, at 11:00 a.m. PT. , , A live Web cast of th...
..., SAN DIEGO, Jan. 6 Orexigen(R) Therapeutics,...ny focused on the treatment of,obesity, today anno...h Annual,J.P. Morgan Healthcare Conference. The de... California, Webcast link: , http://metameetin...
..., Frontier Service Design Creates Tangible Value b... Jan. 6 Frontier Service Design, LLC, a firm that...s that create new and recurring revenue streams fo... around business opportunities that yield new sour...
..., Completed Phase 2 Bladder Augment Trial and Plan...kthrough in Kidney Regeneration Program: Preclini...ON, Pa., Jan. 6 Tengion Inc., a clinical-stage or...ef executive officer, is scheduled to present at t...
..., MILAN, Italy, Jan. 6 A pancreatic cancer pa...reated using a new, faster form of,radiotherapy th... while,extending more advanced care to more patien.... , "We see three major benefits with RapidArc...
..., Rock & Roll Hall of Fame inductees Jackson B...ing attention to the nation,s biggest problem: the...nt Emissary, a DC-based event planning company, an...ll Blue Diamond Ball will be held January 20, 2009...
Other Medicine News:Health News:NuVasive to Present at 27th Annual J.P. Morgan Healthcare Conference 2Health News:First Service Design Firm Launches in United States 2Health News:Tengion to Present at 27th Annual JP Morgan Healthcare Conference 2Health News:First RapidArc Radiotherapy Treatment in Italy Takes Place at Leading Milan Cancer Center 2Health News:First RapidArc Radiotherapy Treatment in Italy Takes Place at Leading Milan Cancer Center 3Health News:Health for All Blue Diamond Ball Scheduled to Celebrate Obama's Inauguration 2
New Image Lock 'n Roll Drainable Pouch, Transparent with Filter
New Image Drainable Pouch,
New Image Drainable Pouch with Filter,
New Image Drainable Mini-Pouch, Beige with Lock 'n Roll
Medicine Products: